ArticleFrontiers in medicine2025
Pulmonary artery pseudoaneurysm-induced massive hemoptysis after chemotherapy combined with tislelizumab for lung squamous cell carcinoma: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of tislelizumab on complete and pathological complete response in non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Diagnosis and embolization of a non-iatrogenic and non-traumatic thyrocervical pseudoaneurysm.CVIR endovascular · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (SCC) is a subtype of non-small cell lung cancer with high incidence and mortality rates. While chemotherapy and immune checkpoint inhibitors (ICIs) have become crucial treatment options for SCC, these may be associated with unforeseen complications. Here, we present a 65-year-old male of hemoptysis caused by a pulmonary artery pseudoaneurysm (PAP) after chemotherapy combined with tislelizumab for lung SCC. After confirmation with angiography, successful embolization was performed to occlude the pseudoaneurysm and proximal artery. To our knowledge, this is the first reported case of PAP formation after chemotherapy combined with tislelizumab for lung SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.